Regeneron Pharmaceuticals (REGN) Receiving Somewhat Positive Media Coverage, Analysis Shows
News headlines about Regeneron Pharmaceuticals (NASDAQ:REGN) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of 0.23 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 45.7722792959756 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Regeneron Announces Appointment of Marion McCourt as Senior Vice President and Head of Commercial (finance.yahoo.com)
- Dane Leone Fears Regeneron Pharmaceuticals Inc Could Be Facing Big Competition from Roche – Smarter Analyst (smarteranalyst.com)
- Regeneron Pharmaceuticals Inc (REGN) Receives Consensus Rating of “Hold” from Brokerages (americanbankingnews.com)
- Regeneron Pharmaceuticals Inc (REGN) Director Sells $325,600.00 in Stock (americanbankingnews.com)
- Regeneron Pharmaceuticals, Inc., (NASDAQ: REGN) – Beta as a Common Measure of Risk – Stock Watch (stocksnewstimes.com)
Several research firms have issued reports on REGN. BTIG Research reiterated a “hold” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday. SunTrust Banks set a $430.00 target price on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research note on Friday, February 9th. Morgan Stanley lifted their target price on Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the company an “equal weight” rating in a research note on Friday, February 9th. Leerink Swann cut their target price on Regeneron Pharmaceuticals from $568.00 to $502.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. Finally, Robert W. Baird upgraded Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Friday, February 9th. They noted that the move was a valuation call. Four analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eleven have assigned a buy rating to the stock. Regeneron Pharmaceuticals has a consensus rating of “Hold” and an average target price of $463.19.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $5.23 EPS for the quarter, topping the Zacks’ consensus estimate of $4.18 by $1.05. Regeneron Pharmaceuticals had a return on equity of 28.48% and a net margin of 20.41%. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the previous year, the company posted $3.04 earnings per share. The company’s revenue was up 28.9% compared to the same quarter last year. analysts expect that Regeneron Pharmaceuticals will post 14.13 EPS for the current fiscal year.
In related news, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 10.80% of the company’s stock.
WARNING: “Regeneron Pharmaceuticals (REGN) Receiving Somewhat Positive Media Coverage, Analysis Shows” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://theolympiareport.com/2018/02/14/regeneron-pharmaceuticals-regn-receiving-somewhat-positive-media-coverage-analysis-shows.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.